1-5 of 5
Paolo B. Abada
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor

Eliana B. Gomez, Kevin Ebata, Hetal S. Randeria, Mary S. Rosendahl, E. Peder Cedervall, Tony H. Morales, Lauren M. Hanson, Nicholas E. Brown, Xueqian Gong, Jennifer Stephens, Wenjuan Wu, Isabel Lippincott, Karin S. Ku, Richard A. Walgren, Paolo B. Abada, Joshua A. Ballard, Charles K. Allerston, Barbara J. Brandhuber
Journal: Blood
Blood (2023) 142 (1): 62–72.
https://doi.org/10.1182/blood.2022018674
Published: 2023
Includes: Supplemental data
Journal Articles

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech-Marańda, Nicole Lamanna, Constantine S. Tam, John F. Seymour, Nirav N. Shah, Catherine C. Coombs, Chaitra S. Ujjani, Manish R. Patel, Bita Fakhri, Chan Y. Cheah, Alvaro J. Alencar, Jonathon B. Cohen, James N. Gerson, Ian W. Flinn, Shuo Ma, Deepa Jagadeesh, Joanna M. Rhodes, Francisco Hernandez-Ilizaliturri, Pier Luigi Zinzani, Minna Balbas, Binoj Nair, Paolo B. Abada, Chunxiao Wang, Denise Wang, Donald E. Tsai, William G. Wierda, Wojciech Jurczak
Journal: Blood
Blood (2022) 140 (Supplement 1): 2316–2320.
https://doi.org/10.1182/blood-2022-159497
Published: 2022
Journal Articles

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Michael L. Wang, Nirav N. Shah, Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, James N. Gerson, Ian W. Flinn, Benoit Tessoulin, Alvaro J. Alencar, Shuo Ma, Ewa Lech-Marańda, Joanna M. Rhodes, Krish Patel, Jennifer A. Woyach, Nicole Lamanna, Yucai Wang, Constantine S. Tam, John F. Seymour, Talha Munir, Hirokazu Nagai, Francisco Hernandez-Ilizaliturri, Anita Kumar, Andrew D. Zelenetz, Preetesh Jain, Binoj Nair, Donald E. Tsai, Minna Balbas, Richard A. Walgren, Paolo B. Abada, Chunxiao Wang, Junjie Zhao, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 9368–9372.
https://doi.org/10.1182/blood-2022-159425
Published: 2022
Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

William G. Wierda, David John Lewis, Paolo Ghia, Nirav N. Shah, Catherine C. Coombs, Chan Y. Cheah, Nicole Lamanna, Joanna M. Rhodes, Marc Hoffmann, Shuo Ma, Toby A. Eyre, Talha Munir, Manish R. Patel, Alvaro J. Alencar, Constantine S. Tam, John F. Seymour, Wojciech Jurczak, Ewa Lech-Marańda, Lindsey E. Roeker, Philip A. Thompson, Paolo B. Abada, Chunxiao Wang, Binoj Nair, Hui Liu, Donald E. Tsai, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 846–849.
https://doi.org/10.1182/blood-2022-157058
Published: 2022
Journal Articles

Outcomes for Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States and Japan: A Study of Two Real-World Databases

Shinya Rai, Lisa M. Hess, Yongmei Chen, Lee Bowman, Paolo B. Abada, Heiko Konig, Richard A. Walgren, Yoshinori Tanizawa, Zhihong Cai, Masaomi Tajimi
Journal: Blood
Blood (2021) 138 (Supplement 1): 4523.
https://doi.org/10.1182/blood-2021-148265
Published: 2021